Total Medical devices industry M&A deals worth $1.4bn were announced globally in April 2022, led by Wallaby Medical’s $541.63m acquisition of Phenox, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 266.2% over the previous month of $390.55m and a drop of 81.4% when compared with the last 12-month average, which stood at $7.68bn.
Comparing M&A deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $883.29m. At the country level, the Germany topped the list in terms of deal value at $541.63m.
In terms of volumes, North America emerged as the top region for Medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe top country in terms of M&A deals activity in April 2022 was the US with 16 deals, followed by the Germany with four and China with two.
In 2022, as of April, Medical devices M&A deals worth $8.59bn were announced globally, marking an increase of 72.6% year on year.
Medical devices industry M&A deals in April 2022: Top deals
The top five M&A deals accounted for 77.9% of the overall value during April 2022.
The combined value of the top five Medical devices M&A deals stood at $1.12bn, against the overall value of $1.4bn recorded for the month.
The top five Medical devices industry M&A deals of April 2022 tracked by GlobalData were:
1) Wallaby Medical $541.63m acquisition deal with Phenox
2) The $170m acquisition of Inform Diagnostics by Fulgent Genetics
3) Integer $141.73m acquisition deal with Aran Biomedical
4) The $140m acquisition of AltheaDx by Castle Biosciences
5) Cochlear $122.03m acquisition deal with Oticon Medical
